Biogen BIIB LEQEMBI — Expense incurred by the collaboration

Similar metrics at other companies

CRSPCollaboration Expense

$45.95M-20.1%

KNSACollaboration Expenses

$75.58M+72.6%

KNSAAccrued Collaboration Expenses Current

$75.58M+40.5%

NUVBCost Of Collaboration And License Agreements Revenue

$5.62M+168%

DCExploration And Evaluation Operating — Labor And Related Expense

$921.14K+110%

CTGOJoint Venture Company — Exploration Expense

$0—

Questions, answered.

What is Biogen's LEQEMBI — expense incurred by the collaboration?

Biogen (BIIB) reported LEQEMBI — expense incurred by the collaboration of $169.5M in Q1 2026.

How has Biogen's LEQEMBI — expense incurred by the collaboration changed year-over-year?

Biogen's LEQEMBI — expense incurred by the collaboration decreased by 4.6% year-over-year, from $177.7M to $169.5M.

What is the long-term trend for Biogen's LEQEMBI — expense incurred by the collaboration?

Over 3 years (2022 to 2025), Biogen's LEQEMBI — expense incurred by the collaboration has grown at a 88.6% compound annual growth rate (CAGR), from $104.6M to $701.6M.

What does LEQEMBI — expense incurred by the collaboration mean?

This metric captures the total operational and development expenses generated by a collaborative entity or joint venture for a specific product line. It serves as a comprehensive view of the total resource consumption of the partnership, independent of how those costs are allocated or reported on the individual partners' financial statements. It is a key indicator of the overall scale and intensity of the collaborative effort.